Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Gust

Showing results (171-180 of 181) with videos related to

Pageof 19
Sort By:
Archiv Der Pharmazie|June 10, 2004
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen levelSabine Schertl, Rolf W Hartmann, Christine Batzl-Hartmann, et al.
Journal of Cancer Research and Clinical Oncology|October 7, 2006
Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studiesSabine Schertl, Rolf W Hartmann, Christine Batzl-Hartmann, et al.
Journal of Medicinal Chemistry|December 18, 2024
Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan DerivativesAnna M Schoepf, Maximilian Gebhart, Martin Federspiel, et al.
European Journal of Medicinal Chemistry|February 8, 2011
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivativesWukun Liu, Jinpei Zhou, Kerstin Bensdorf, et al.
Journal of Medicinal Chemistry|April 17, 2026
Stereochemical Aspects in the Context of the Structure-Activity Relationship of Chlorido[<i>N</i>,<i>N</i>'-bis(chloro/bromosalicylidene)-1,2-diphenyl-1,2-diaminoethane]iron(III) ComplexesAstrid Dagmar Bernkop-Schnürch, Stefanie Schwarz, Philipp Rigo, et al.
Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry|March 5, 2009
[N,N'-Bis(salicylidene)-1,2-phenylenediamine]metal complexes with cell death promoting propertiesAnnegret Hille, Ingo Ott, Ana Kitanovic, et al.
Hypertension (Dallas, Tex. : 1979)|August 19, 2009
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activationKai Kappert, Oleg Tsuprykov, Jan Kaufmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2010
Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerizationLuise Richter, Lisa-Marie Munter, Julia Ness, et al.
Redox Biology|July 2, 2024
Iron(III)-salophene catalyzes redox cycles that induce phospholipid peroxidation and deplete cancer cells of ferroptosis-protecting cofactorsFengting Su, Hubert Descher, Minh Bui-Hoang, et al.
Oncogene|October 9, 2019
A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastomaStefan Salcher, Gilles Spoden, Judith Hagenbuchner, et al.
Pageof 19

Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
Archiv Der Pharmazie|June 10, 2004
[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen levelSabine Schertl, Rolf W Hartmann, Christine Batzl-Hartmann, et al.
Journal of Cancer Research and Clinical Oncology|October 7, 2006
Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studiesSabine Schertl, Rolf W Hartmann, Christine Batzl-Hartmann, et al.
Journal of Medicinal Chemistry|December 18, 2024
Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan DerivativesAnna M Schoepf, Maximilian Gebhart, Martin Federspiel, et al.
European Journal of Medicinal Chemistry|February 8, 2011
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivativesWukun Liu, Jinpei Zhou, Kerstin Bensdorf, et al.
Journal of Medicinal Chemistry|April 17, 2026
Stereochemical Aspects in the Context of the Structure-Activity Relationship of Chlorido[<i>N</i>,<i>N</i>'-bis(chloro/bromosalicylidene)-1,2-diphenyl-1,2-diaminoethane]iron(III) ComplexesAstrid Dagmar Bernkop-Schnürch, Stefanie Schwarz, Philipp Rigo, et al.
Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry|March 5, 2009
[N,N'-Bis(salicylidene)-1,2-phenylenediamine]metal complexes with cell death promoting propertiesAnnegret Hille, Ingo Ott, Ana Kitanovic, et al.
Hypertension (Dallas, Tex. : 1979)|August 19, 2009
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activationKai Kappert, Oleg Tsuprykov, Jan Kaufmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2010
Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerizationLuise Richter, Lisa-Marie Munter, Julia Ness, et al.
Redox Biology|July 2, 2024
Iron(III)-salophene catalyzes redox cycles that induce phospholipid peroxidation and deplete cancer cells of ferroptosis-protecting cofactorsFengting Su, Hubert Descher, Minh Bui-Hoang, et al.
Oncogene|October 9, 2019
A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastomaStefan Salcher, Gilles Spoden, Judith Hagenbuchner, et al.
Pageof 19